Acasti Pharma (ACST)
(Real Time Quote from BATS)
$3.03 USD
+0.13 (4.48%)
Updated Apr 25, 2024 01:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Income Statements
Fiscal Year end for Acasti Pharma, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 52 | 16 | 17 | 24 |
Income After Depreciation & Amortization | 0 | -52 | -16 | -16 | -24 |
Non-Operating Income | NA | 0 | 5 | 0 | 0 |
Interest Expense | NA | 0 | 0 | 3 | 1 |
Pretax Income | NA | -52 | -10 | -20 | -26 |
Income Taxes | NA | -10 | -1 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -42 | -10 | -20 | -26 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -42 | -10 | -20 | -26 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -52 | -16 | -16 | -22 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 1 | 2 |
Income After Depreciation & Amortization | 0 | -52 | -16 | -16 | -24 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 7.44 | 6.14 | 2.47 | 1.76 |
Diluted EPS Before Non-Recurring Items | NA | -2.10 | -1.62 | -5.76 | -11.04 |
Diluted Net EPS (GAAP) | NA | -5.70 | -1.62 | -8.16 | -14.40 |
Fiscal Year end for Acasti Pharma, Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 3.04 | 2.09 | 4.46 | 4.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -3.04 | -2.09 | -4.46 | -4.16 |
Non-Operating Income | NA | 0.44 | -1.63 | 0.14 | 0.08 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | -0.04 |
Pretax Income | NA | -2.60 | -3.72 | -4.31 | -37.96 |
Income Taxes | NA | -0.21 | -0.45 | -0.29 | -8.87 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -2.39 | -3.27 | -4.02 | -29.09 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -2.39 | -3.27 | -4.02 | -29.09 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 11.51 | 7.55 | 7.44 | 7.46 |
Diluted EPS Before Non-Recurring Items | NA | -0.21 | -0.19 | -0.34 | -0.30 |
Diluted Net EPS (GAAP) | NA | -0.21 | -0.43 | -0.54 | -3.90 |